Visceral leishmaniasis treatment, Italy
- PMID: 14720406
- PMCID: PMC3034325
- DOI: 10.3201/eid0912.030178
Visceral leishmaniasis treatment, Italy
Abstract
First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.
Figures


References
-
- Gradoni L. Epizootiology of canine leishmaniasis in southern Europe. In: R. Killick-Kendrick, editor. Canine leishmaniasis: an update. Proceedings of the Canine Leishmaniasis Forum, Barcelona, Spain. Wiesbaden, Germany: Hoechst Roussel Vet; 1999. p. 32–9.
-
- del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, et al. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis. 2002;186:1366–70. 10.1086/344325 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous